10x Genomics, Inc.

8-K · txg-20260604.htm iXBRL

0001770787 2026-06-04 2026-06-04

 UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 ______________________
 FORM 8-K
 ______________________
 CURRENT REPORT
 Pursuant to Section 13 or 15(d)
 of the Securities Exchange Act of 1934
 Date of Report (Date of earliest event reported): June 4, 2026

 10x Genomics, Inc.
 (Exact name of registrant as specified in its charter)

 Delaware
 001-39035
 45-5614458

 (State or other jurisdiction
 of incorporation)
 (Commission
 File Number)
 (IRS Employer
 Identification No.)

 6230 Stoneridge Mall Road
 Pleasanton , California 94588
 ( 925 ) 401-7300
 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
 ___________________________
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 ☐
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 ☐
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 ☐
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 ☐
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

 Securities registered pursuant to Section 12(b) of the Act:

 Title of each class
 Trading
 Symbol
 Name of each exchange
 on which registered

 Class A common stock, par value $0.00001 per share
 TXG
 The Nasdaq Stock Market LLC

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 Emerging growth company   ☐
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 Item 5.07 Submission of Matters to a Vote of Security Holders

 The annual meeting of stockholders of 10x Genomics, Inc. (the "Company") was held on June 4, 2026 via live webcast (the “Annual Meeting”). At the Annual Meeting, there were present, virtually or by proxy, holders of 117,542,161 shares of the Company's Class A and Class B common stock, representing 198,815,518, or approximately 90.5%, of the 219,700,782 eligible votes, constituting a quorum. The matters submitted to a vote at the Annual Meeting and the final voting results of such matters were as follows:

 Proposal 1 - Election of Directors

 The Company’s stockholders approved the election of three Class I directors, each to hold office for a three-year term expiring at the Company’s 2029 annual meeting of stockholders or until his respective successor has been duly elected and qualified or until his earlier resignation or removal. The final voting results were as follows:

 Nominee Votes For Votes Against Abstentions Broker Non-Votes
 Serge Saxonov 164,137,381 15,559,860 557,329 18,560,948
 Benjamin J. Hindson 162,942,766 16,761,532 550,270 18,560,950
 John R. Stuelpnagel 155,628,365 24,072,179 554,023 18,560,951

 Proposal 2 - Ratification of Independent Registered Public Accounting Firm

 The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026. There were no broker non-votes on this proposal. The final voting results were as follows:

 Votes For Votes Against Abstentions Broker Non-Votes
 197,719,939 458,231 637,346 — 

 Proposal 3 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers

 The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as described in more detail in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 24, 2026. The final voting results were as follows:

 Votes For Votes Against Abstentions Broker Non-Votes
 176,677,540 2,828,730 748,296 18,560,952

 Signatures
 Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 10x Genomics, Inc.

 By:
 /s/ Randy Wu
 Name:
 Randy Wu
 Title:
 General Counsel and Secretary

 Date: June 8, 2026